InflaRx Announces Pricing of $150 Million Underwritten Offering of Ordinary Shares
InflaRx N.V., a biopharmaceutical firm focused on anti-inflammatory therapeutics, announced a $150 million underwritten offering of 75 million ordinary shares at $2.00 per share. The proceeds are intended to support clinical pipeline advancement, working capital, and general corporate purposes. The offering includes participation from several healt…